 |
Novo Nordisk, Ebn Sina Medical launch Wegovy in QatarEbn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish global healthcare company, have announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar. The event was attended by Anders Bjø More… |
 |
PureHealth reports 3% rise in Q1 net profit to $137.5mPureHealth Holding, a leading healthcare group in the Middle East, reported a revenue increase of 8% year-on-year to AED6.6 billion ($1.8 billion) driven by growth across all of PureHealth’s segments. EBITDA grew 5% year-on-year to AED1.1 billion a More… |
 |
Novo Nordisk in deal to produce weight loss drug in KSANovo Nordisk, a leading global healthcare company, has announced the signing of a MoU with Lifera, a biopharmaceutical company owned by the Saudi sovereign wealth fund PIF (Public Investment Fund), to pursue the localisation of the manufacturing of semaglutide GLP-1 treatments in Saudi Arabia More… |
 |
Red Sea Global launches region's largest ornamental plants nurseryRed Sea Global (RSG), the developer behind regenerative tourism destinations The Red Sea and AMAALA, has announced the launch of its new brand, Botanica - the new name for The Red Sea Landscape Nursery which is dedicated to sustainable greenery across RSG’s destinations, while a More… |
 |
e&, LifeBot to bring telemedicine solutions to UAE’s critical sectorse& enterprise, the digital transformation arm of UAE telco e&, has established a strategic partnership with leading telemedicine solutions provider, LifeBot, to deliver industry grade virtual care services in demanding environments and critical sectors in the UAE. More… |
 |
Dubai to host World Green Economy Summit in OctoberThe World Green Economy Organisation will organise the 11th World Green Economy Summit (WGES) on October 1 and 2 at the Dubai World Trade Centre. WGES 2025 will be held under the patronage of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President a More… |
 |
Lilly's oral GLP-1 demonstrates significant efficacy resultsEli Lilly and Company has announced positive topline Phase 3 results from Achieve-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orfor More… |
